Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Immutep Ltd ( (AU:IMM) ) has provided an update.
Immutep Limited announced a poster presentation for its pivotal TACTI-004 Phase III trial at the European Lung Cancer Congress 2025. The trial evaluates the combination of Immutep’s eftilagimod alfa with KEYTRUDA and chemotherapy for advanced non-small cell lung cancer. This global trial, enrolling 750 patients across 25 countries, aims to potentially shift treatment paradigms for this cancer type, irrespective of PD-L1 expression, and confirms the promising safety and efficacy of the treatment.
More about Immutep Ltd
Immutep Limited is a late-stage biotechnology company focused on developing novel immunotherapies for cancer and autoimmune diseases. The company is a leader in the field of Lymphocyte Activation Gene-3 (LAG-3) therapeutics, aiming to either stimulate or suppress the immune response. Immutep’s diverse product portfolio is designed to offer innovative treatment options to patients and maximize shareholder value.
YTD Price Performance: -9.09%
Average Trading Volume: 5,000
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $273.1M
For a thorough assessment of IMM stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue